Safe Stop Ipilimumab-nivolumab (IPI-NIVO) Trial

Clinical trial NCT05652673 · RECRUITING

Trial details

NCT number: NCT05652673
Sponsor: Erasmus Medical Center
Status: RECRUITING
Phase: Not Applicable
Study type: INTERVENTIONAL

Melanoma Stage IV Melanoma Stage III Immunotherapy Toxicity, Drug

Start date: 2023-02-01
Primary completion: 2025-12-01
Enrollment: 80

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.